PATH compared with AUTL: revenue, margins and what each company keeps, and the suppliers and customers both name

PATHUiPath, Inc.

Mkt capRevenueRevenue

AUTLAutolus Therapeutics plc

Mkt capRevenueRevenue

Compare

PATHUiPath, Inc.

AUTLAutolus Therapeutics plc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

AUTL: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only PATH 0

None

Shared 0

No disclosed counterparties: PATH.

Only AUTL 4

MRNAModernacustomer

BNTXBioNTechcustomer

—Miltenyi Biotec GmbHunlistedsupplier

—University College of London Businessunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

PATH, solidAUTL, dashed

PATHUiPath, Inc.

13.72▼−0.46%· post 13.71

Mkt cap$7.2BRevenue$410MQ2 FY27Revenue$1.6BFY26

AUTLAutolus Therapeutics plc

1.51▼−4.43%· post 1.51

ClosedOct 30 '26

Mkt cap$404.6MRevenue$46MQ2 FY26Revenue$75MFY25

Compare

ClosedOct 30 '26

PATHUiPath, Inc.

AUTLAutolus Therapeutics plc

13.72▼−0.46%post 13.71

Price

1.51▼−4.43%post 1.51

$7.2B

Mkt cap

$404.6M

Q2 FY27$410M

Revenue

$46MQ2 FY26

FY26$1.6B

Revenue

$75MFY25

PATH13.72▼−0.46%vsAUTL1.51▼−4.43%ClosedOct 30 '26